Juvenile Dermatomyositis and Nephrotic Syndrome: A Case Report and a Mini Literature Review

Overview

Journal Front Pediatr

Specialty Pediatrics

Date 2023 May 19

PMID 37205220

Authors

Weiran Zhou

Linlin Dong

Xuemei Liu

Chunhua Dong

Hongxia Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Renal involvement is rarely reported in juvenile dermatomyositis and may be caused by the toxic effects of myoglobinuria or an autoimmune reaction. We report a case of dermatomyositis and nephrotic syndrome in a child to explore the association between juvenile dermatomyositis and renal involvement.

Case Presentation: An 8-year-old girl with skin rash, edema, proximal muscle weakness predominantly involving the lower extremities, low-grade fever, and foamy urine was admitted to our hospital. Her laboratory tests met the criteria of nephrotic syndrome. She had elevated creatine kinase and lactate dehydrogenase and was diagnosed with juvenile dermatomyositis after electromyography and muscle MRI. Anti-NXP2 antibodies were positive. Her proteinuria was relieved soon after treatment with prednisone and methotrexate, but her muscle strength progressively decreased. The disease was relieved after pulse methylprednisolone treatment and mycophenolate mofetil, but recurred after drug reduction with mild proteinuria. Adalimumab was used for treatment and helped reduce the doses of glucocorticoid and mycophenolate mofetil.

Conclusion: Juvenile dermatomyositis may be one of the rare causes of nephrotic syndrome. The mechanism involved in JDM combined with renal injury may be multifactorial. Autoantibodies may play important roles in both muscle and renal damage.

References

Niewold T, Kariuki S, Morgan G, Shrestha S, Pachman L . Gene-gene-sex interaction in cytokine gene polymorphisms revealed by serum interferon alpha phenotype in juvenile dermatomyositis. J Pediatr. 2010; 157(4):653-7. PMC: 2936662. DOI: 10.1016/j.jpeds.2010.04.034. View

Moghadam-Kia S, Oddis C, Aggarwal R . Modern Therapies for Idiopathic Inflammatory Myopathies (IIMs): Role of Biologics. Clin Rev Allergy Immunol. 2016; 52(1):81-87. PMC: 4945479. DOI: 10.1007/s12016-016-8530-2. View

Yan T, Zhang X, Yang H, Sun W, Liu L, Du Y . Association of anti-NXP2 antibody with clinical characteristics and outcomes in adult dermatomyositis: results from clinical applications based on a myositis-specific antibody. Clin Rheumatol. 2021; 40(9):3695-3702. DOI: 10.1007/s10067-021-05667-x. View

Iwata N, Nakaseko H, Kohagura T, Yasuoka R, Abe N, Kawabe S . Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: Experience at a single center in Japan. Mod Rheumatol. 2018; 29(5):802-807. DOI: 10.1080/14397595.2018.1511025. View

Cucchiari D, Angelini C . Renal Involvement in Idiopathic Inflammatory Myopathies. Clin Rev Allergy Immunol. 2015; 52(1):99-107. DOI: 10.1007/s12016-015-8524-5. View

Campanilho-Marques R, Deakin C, Simou S, Papadopoulou C, Wedderburn L, Pilkington C . Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients. Arthritis Res Ther. 2020; 22(1):79. PMC: 7161150. DOI: 10.1186/s13075-020-02164-5. View

Nickavar A, Mehr Azma M . Nephrotic syndrome and juvenile dermatomyositis. Rheumatol Int. 2011; 32(9):2933-5. DOI: 10.1007/s00296-011-2028-2. View

Tesfamariam B, Defelice A . Endothelial injury in the initiation and progression of vascular disorders. Vascul Pharmacol. 2007; 46(4):229-37. DOI: 10.1016/j.vph.2006.11.005. View

Soylu A, Kavukcu S, Turkmen M, Saroglu S . Dermatomyositis with membranous nephropathy. Turk J Pediatr. 2001; 43(2):143-5. View

10.

Martin N, Krol P, Smith S, Murray K, Pilkington C, Davidson J . A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years' experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory.... Rheumatology (Oxford). 2010; 50(1):137-45. PMC: 2999955. DOI: 10.1093/rheumatology/keq261. View

11.

Mantoo M, Tripathy S, Phulware R, Bagri N, Hari P, Barwad A . Juvenile dermatomyositis with IgA nephropathy: case-based review. Rheumatol Int. 2018; 39(3):577-581. DOI: 10.1007/s00296-018-4229-4. View

12.

Wu J, Lu M, Reed A . Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment. World J Pediatr. 2019; 16(1):31-43. DOI: 10.1007/s12519-019-00313-8. View

13.

Couvrat-Desvergnes G, Masseau A, Benveniste O, Bruel A, Hervier B, Mussini J . The spectrum of renal involvement in patients with inflammatory myopathies. Medicine (Baltimore). 2014; 93(1):33-41. PMC: 4616328. DOI: 10.1097/MD.0000000000000015. View

14.

Li D, Tansley S . Juvenile Dermatomyositis-Clinical Phenotypes. Curr Rheumatol Rep. 2019; 21(12):74. PMC: 6906215. DOI: 10.1007/s11926-019-0871-4. View

15.

Leung A, Lam J, Alobaida S, Leong K, Wong A . Juvenile Dermatomyositis: Advances in Pathogenesis, Assessment, and Management. Curr Pediatr Rev. 2021; 17(4):273-287. DOI: 10.2174/1573396317666210426105045. View

16.

Aouizerate J, Antonio M, Bader-Meunier B, Barnerias C, Bodemer C, Isapof A . Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juvenile dermatomyositis. Rheumatology (Oxford). 2018; 57(5):873-879. DOI: 10.1093/rheumatology/kex516. View

17.

Papadopoulou C, McCann L . The Vasculopathy of Juvenile Dermatomyositis. Front Pediatr. 2018; 6:284. PMC: 6189418. DOI: 10.3389/fped.2018.00284. View

18.

Hamadeh M, Boustany S, Fares J . Acute Kidney Injury Following Dermatomyositis. Clin Med Res. 2019; 17(3-4):102-104. PMC: 6886894. DOI: 10.3121/cmr.2019.1487. View

19.

Wang X, Ding Y, Zhou Z, Hou J, Xu Y, Li J . Clinical characteristics and poor predictors of anti-NXP2 antibody-associated Chinese JDM children. Pediatr Rheumatol Online J. 2021; 19(1):6. PMC: 7788734. DOI: 10.1186/s12969-020-00492-z. View

20.

McCann L, Livermore P, Wilkinson M, Wedderburn L . Juvenile dermatomyositis. Where are we now?. Clin Exp Rheumatol. 2022; 40(2):394-403. DOI: 10.55563/clinexprheumatol/56ilob. View